MA38147A1 - Composés ayant une activité antagoniste du récepteur muscarinique et agoniste du récepteur bêta2 adrénergique - Google Patents
Composés ayant une activité antagoniste du récepteur muscarinique et agoniste du récepteur bêta2 adrénergiqueInfo
- Publication number
- MA38147A1 MA38147A1 MA38147A MA38147A MA38147A1 MA 38147 A1 MA38147 A1 MA 38147A1 MA 38147 A MA38147 A MA 38147A MA 38147 A MA38147 A MA 38147A MA 38147 A1 MA38147 A1 MA 38147A1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- antagonist activity
- beta2 adrenergic
- adrenergic receptor
- receptor antagonist
- Prior art date
Links
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 title abstract 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 title abstract 2
- 239000000048 adrenergic agonist Substances 0.000 title abstract 2
- 229940126157 adrenergic receptor agonist Drugs 0.000 title abstract 2
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title 1
- 239000003149 muscarinic antagonist Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne des composés agissant à la fois en tant qu'antagonistes du récepteur muscarinique et agonistes du récepteur bêta2 adrénergique, des procédés pour leur préparation, des compositions les comprenant, des utilisations thérapeutiques et des combinaisons avec d'autres principes pharmaceutiquement actifs.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12195891 | 2012-12-06 | ||
| PCT/EP2013/075661 WO2014086924A1 (fr) | 2012-12-06 | 2013-12-05 | Composés ayant une activité antagoniste du récepteur muscarinique et agoniste du récepteur bêta2 adrénergique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38147A1 true MA38147A1 (fr) | 2018-03-30 |
| MA38147B1 MA38147B1 (fr) | 2018-09-28 |
Family
ID=47323975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38147A MA38147B1 (fr) | 2012-12-06 | 2013-12-05 | Composés ayant une activité antagoniste du récepteur muscarinique et agoniste du récepteur bêta2 adrénergique |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US8987299B2 (fr) |
| EP (2) | EP3345904B1 (fr) |
| JP (1) | JP6421989B2 (fr) |
| KR (2) | KR102156443B1 (fr) |
| CN (1) | CN104822678B (fr) |
| AR (1) | AR093825A1 (fr) |
| AU (1) | AU2013354043C1 (fr) |
| BR (1) | BR112015012730B1 (fr) |
| CA (1) | CA2893626C (fr) |
| CL (1) | CL2015001483A1 (fr) |
| CO (1) | CO7400870A2 (fr) |
| CY (2) | CY1120159T1 (fr) |
| DK (2) | DK2928889T3 (fr) |
| EA (1) | EA030552B1 (fr) |
| ES (2) | ES2670686T3 (fr) |
| GE (1) | GEP20186839B (fr) |
| HR (2) | HRP20180915T1 (fr) |
| HU (2) | HUE051394T2 (fr) |
| IL (1) | IL239182B (fr) |
| LT (2) | LT3345904T (fr) |
| MA (1) | MA38147B1 (fr) |
| MX (1) | MX369311B (fr) |
| NZ (1) | NZ708738A (fr) |
| PE (1) | PE20151216A1 (fr) |
| PH (1) | PH12015501247B1 (fr) |
| PL (2) | PL2928889T3 (fr) |
| PT (2) | PT3345904T (fr) |
| RS (2) | RS60864B1 (fr) |
| SA (1) | SA515360514B1 (fr) |
| SG (2) | SG11201504318UA (fr) |
| SI (2) | SI3345904T1 (fr) |
| TN (1) | TN2015000244A1 (fr) |
| TR (1) | TR201808698T4 (fr) |
| TW (1) | TWI637954B (fr) |
| UA (1) | UA118181C2 (fr) |
| WO (1) | WO2014086924A1 (fr) |
| ZA (1) | ZA201503965B (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20110083U1 (it) | 2010-05-13 | 2011-11-14 | De La Cruz Jose Antonio Freire | Piastra per la costruzione di carrelli per aeroplani |
| EP2386555A1 (fr) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | Nouveaux dérivés de cyclohéxylamine dotés d'activités agoniste bêta 2 adrénergique et antagoniste muscarinique m3 |
| EP2592078A1 (fr) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | Nouveaux dérivés de cyclohéxylamine dotés d'activités agonistes bêta 2 adrénergique et antagoniste muscarinique M3 |
| RU2661877C2 (ru) * | 2012-12-06 | 2018-07-20 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов |
| MX369311B (es) * | 2012-12-06 | 2019-11-05 | Chiesi Farm Spa | Compuestos con actividad antagonista de los receptores muscarinicos y actividad agonista del receptor beta2 adrenergico. |
| EP2934594B1 (fr) | 2012-12-18 | 2019-09-04 | Almirall, S.A. | Dérivés de cyclohéxyle et de quinuclidinyle de carbamate présentant des activités agonistes bêta2-adrénergiques et antagonistes muscariniques m3 |
| TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
| TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽 |
| TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有ｍａｂａ化合物和皮質類固醇之組合 |
| TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物 |
| TWI703138B (zh) | 2015-02-12 | 2020-09-01 | 義大利商吉斯藥品公司 | 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物 |
| AR104828A1 (es) * | 2015-06-01 | 2017-08-16 | Chiesi Farm Spa | COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO |
| SI3377108T1 (sl) * | 2015-11-16 | 2020-05-29 | Chiesi Farmaceutici S.P.A. | Postopek za pripravo suhe praškaste formulacije, ki obsega antiholinergik, kortikosteroid in beta-adrenergik |
| EP3383867B1 (fr) | 2015-12-03 | 2021-04-14 | Chiesi Farmaceutici S.p.A. | Composes dotes d'une activite antagoniste du recepteur muscarinique et agoniste du recepteur adrenergique beta2 |
| WO2018011090A1 (fr) | 2016-07-13 | 2018-01-18 | Chiesi Farmaceutici S.P.A. | Composés d'hydroxyquinolinone ayant une activité d'antagoniste des récepteurs muscariniques et d'agoniste des récepteurs adrénergiques bêta2 |
| CA2994290C (fr) | 2017-11-06 | 2024-01-23 | Entech Solution As | Methode et manchon de stimulation destines a la completion de puits dans un puits de forage souterrain |
| EP4365162A3 (fr) * | 2020-12-21 | 2024-10-09 | Intervet International B.V. | Procédé de préparation de n-(bis(4-méthoxyphényl)méthyl)-6-oxo-2-(pyridazin-3-yl)-1,6-dihydropyrimidine-5-carboxamide |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2222128A (en) | 1937-01-29 | 1940-11-19 | Pure Oil Co | Preparation and separation of aromatic hydrocarbons |
| DE19921693A1 (de) | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
| BR0315234A (pt) | 2002-10-11 | 2005-08-23 | Pfizer | Derivados de indol como agonistas beta-2 |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| US7345060B2 (en) | 2003-11-21 | 2008-03-18 | Theravance, Inc. | Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| ES2289691T3 (es) | 2004-01-22 | 2008-02-01 | Pfizer, Inc. | Derivados de sulfonamida para el tratamiento de enfermedades. |
| WO2005092861A1 (fr) | 2004-03-11 | 2005-10-06 | Pfizer Limited | Derives de quinolinone compositions pharmaceutiques contenant ces derives et utilisation de celles-ci |
| US7538141B2 (en) | 2004-03-23 | 2009-05-26 | Alan Daniel Brown | Compounds for the treatment of diseases |
| WO2005092840A1 (fr) | 2004-03-23 | 2005-10-06 | Pfizer Limited | Derives de formamide utiles comme recepteurs adrenergiques |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| EP1778626A1 (fr) | 2004-08-16 | 2007-05-02 | Theravance, Inc. | Composes a activite agoniste pour recepteur beta2 adrenergique et antagoniste pour recepteur muscarinique |
| EP1833822A2 (fr) | 2004-08-16 | 2007-09-19 | Theravance, Inc. | Composes a activite agoniste pour recepteur beta2 adrenergique et antagoniste pour recepteur muscarinique |
| FR2898640B1 (fr) | 2006-03-20 | 2008-04-25 | Siemens Vdo Automotive Sas | Procede de transmission d'information relatif au fonctionnement d'un moteur a combustion interne |
| EP2080523A1 (fr) * | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Compositions comprenant un agent anti-muscarinique et un bêta-agoniste longue action |
| WO2010123766A1 (fr) | 2009-04-23 | 2010-10-28 | Theravance, Inc. | Composes diamides ayant un antagoniste du recepteur muscarinique et une activite agoniste des recepteurs adrenergiques beta2 |
| US9072734B2 (en) * | 2009-04-30 | 2015-07-07 | Teijin Pharma Limited | Quaternary ammonium salt compounds |
| WO2011048409A1 (fr) | 2009-10-20 | 2011-04-28 | Astrazeneca Ab | Dérivés d'amine cyclique ayant une activité agoniste de récepteur adrénergique bêta-2 et antagoniste de récepteur muscarinique |
| EP2718281B1 (fr) | 2011-06-10 | 2015-09-09 | Chiesi Farmaceutici S.p.A. | Composés ayant une activité antagoniste des récepteurs muscariniques et une activité agoniste des récepteurs adrénergique bêta-2 |
| HRP20151317T1 (hr) * | 2011-06-10 | 2016-01-01 | Chiesi Farmaceutici S.P.A. | Spojevi koji pokazuju aktivnost prema antagonistima muskarinskog receptora i beta2 adrenergiäśnog receptora |
| MX369311B (es) * | 2012-12-06 | 2019-11-05 | Chiesi Farm Spa | Compuestos con actividad antagonista de los receptores muscarinicos y actividad agonista del receptor beta2 adrenergico. |
| RU2661877C2 (ru) * | 2012-12-06 | 2018-07-20 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов |
-
2013
- 2013-12-05 MX MX2015006788A patent/MX369311B/es active IP Right Grant
- 2013-12-05 AU AU2013354043A patent/AU2013354043C1/en not_active Ceased
- 2013-12-05 SI SI201331764T patent/SI3345904T1/sl unknown
- 2013-12-05 SI SI201330994T patent/SI2928889T1/en unknown
- 2013-12-05 HU HUE18156043A patent/HUE051394T2/hu unknown
- 2013-12-05 GE GEAP201313845A patent/GEP20186839B/en unknown
- 2013-12-05 PT PT181560434T patent/PT3345904T/pt unknown
- 2013-12-05 CN CN201380063365.2A patent/CN104822678B/zh not_active Expired - Fee Related
- 2013-12-05 NZ NZ708738A patent/NZ708738A/en not_active IP Right Cessation
- 2013-12-05 EP EP18156043.4A patent/EP3345904B1/fr active Active
- 2013-12-05 MA MA38147A patent/MA38147B1/fr unknown
- 2013-12-05 PT PT138118278T patent/PT2928889T/pt unknown
- 2013-12-05 HR HRP20180915TT patent/HRP20180915T1/hr unknown
- 2013-12-05 JP JP2015546012A patent/JP6421989B2/ja not_active Expired - Fee Related
- 2013-12-05 EA EA201590873A patent/EA030552B1/ru unknown
- 2013-12-05 UA UAA201505478A patent/UA118181C2/uk unknown
- 2013-12-05 PL PL13811827T patent/PL2928889T3/pl unknown
- 2013-12-05 DK DK13811827.8T patent/DK2928889T3/en active
- 2013-12-05 BR BR112015012730-4A patent/BR112015012730B1/pt not_active IP Right Cessation
- 2013-12-05 DK DK18156043.4T patent/DK3345904T3/da active
- 2013-12-05 PE PE2015000738A patent/PE20151216A1/es active IP Right Grant
- 2013-12-05 PL PL18156043T patent/PL3345904T3/pl unknown
- 2013-12-05 TW TW102144561A patent/TWI637954B/zh not_active IP Right Cessation
- 2013-12-05 LT LTEP18156043.4T patent/LT3345904T/lt unknown
- 2013-12-05 KR KR1020157014956A patent/KR102156443B1/ko not_active Expired - Fee Related
- 2013-12-05 LT LTEP13811827.8T patent/LT2928889T/lt unknown
- 2013-12-05 AR ARP130104529A patent/AR093825A1/es unknown
- 2013-12-05 TR TR2018/08698T patent/TR201808698T4/tr unknown
- 2013-12-05 KR KR1020207006181A patent/KR102240459B1/ko active Active
- 2013-12-05 EP EP13811827.8A patent/EP2928889B1/fr active Active
- 2013-12-05 SG SG11201504318UA patent/SG11201504318UA/en unknown
- 2013-12-05 RS RS20201150A patent/RS60864B1/sr unknown
- 2013-12-05 HU HUE13811827A patent/HUE037944T2/hu unknown
- 2013-12-05 ES ES13811827.8T patent/ES2670686T3/es active Active
- 2013-12-05 SG SG10201704032RA patent/SG10201704032RA/en unknown
- 2013-12-05 ES ES18156043T patent/ES2816210T3/es active Active
- 2013-12-05 WO PCT/EP2013/075661 patent/WO2014086924A1/fr not_active Ceased
- 2013-12-05 RS RS20180529A patent/RS57232B1/sr unknown
- 2013-12-05 CA CA2893626A patent/CA2893626C/fr active Active
- 2013-12-06 US US14/098,735 patent/US8987299B2/en active Active
-
2015
- 2015-01-23 US US14/603,926 patent/US9371318B2/en active Active
- 2015-06-02 CL CL2015001483A patent/CL2015001483A1/es unknown
- 2015-06-03 CO CO15127118A patent/CO7400870A2/es unknown
- 2015-06-03 IL IL239182A patent/IL239182B/en active IP Right Grant
- 2015-06-03 ZA ZA2015/03965A patent/ZA201503965B/en unknown
- 2015-06-03 PH PH12015501247A patent/PH12015501247B1/en unknown
- 2015-06-03 SA SA515360514A patent/SA515360514B1/ar unknown
- 2015-06-03 TN TNP2015000244A patent/TN2015000244A1/fr unknown
-
2018
- 2018-05-03 CY CY20181100469T patent/CY1120159T1/el unknown
-
2020
- 2020-09-09 HR HRP20201435TT patent/HRP20201435T1/hr unknown
- 2020-09-28 CY CY20201100912T patent/CY1123365T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38147A1 (fr) | Composés ayant une activité antagoniste du récepteur muscarinique et agoniste du récepteur bêta2 adrénergique | |
| MA35187B1 (fr) | Composés ayant une activité antagoniste d'un récepteur muscarinique et agoniste d'un récepteur béta2 adrénergique | |
| MA38325A2 (fr) | Dérivés de benzothiophène et compositions correspondantes en tant qu'agents de dégradation sélectifs des récepteurs des œstrogènes | |
| BR112015012746A2 (pt) | compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos | |
| EP2614860A4 (fr) | Composition pharmaceutique pour le traitement de l'oeil sec | |
| PH12017501424B1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| MX2011011156A (es) | COMPUESTOS DIAMIDA QUE TIENE ACTIVIDAD COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS Y COMO AGONISTAS DE LOS RECEPTORES ANDRENERGICOS ß2. | |
| MA38260A1 (fr) | Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3 | |
| MA35893B1 (fr) | Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7 | |
| MA43256B1 (fr) | Procédé pour préparer une formulation de poudre sèche comprenant un anticholinergique, un corticostéroïde et un bêta-adrénergique | |
| MA35268B1 (fr) | 1-pipérazino-3-phénylindanes deutérés pour le traitement de la schizophrénie | |
| MA32061B1 (fr) | Triazolopyridazines en tant qu'inhibiteurs de par1, production de celles-ci, et utilisation en tant que médicaments | |
| EA201001842A1 (ru) | Новые соединения, обладающие активностью антагонистов мускариновых рецепторов | |
| AR089112A1 (es) | Asociacion entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un antagonista de los receptores nmda y las composiciones farmaceuticas que la contienen | |
| BR112017023484A2 (pt) | compostos tendo atividade de antagonista de receptor muscarínico e agonista de receptor beta2 adrenérgico | |
| TN2013000429A1 (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| UA109581C2 (uk) | Сполуки з активністю антагоністів мускаринових рецепторів і агоністів адренергічного рецептора бета2 | |
| MA39054B1 (fr) | Dérivés pyridyle bicycliques à anneaux fusionnés utilisés en tant qu'inhibiteurs de fgfr4 |